Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by allinenergy2on Aug 14, 2015 7:31am

144 Views

Post# 24017606

200K Shorts as of July 31, 2015

Don't know what the up to date figure is, as the tsx venture site updates every 2 weeks.

Maybe Casus will be able to pick some up cheap as he stated that was his intention. Good luck to all here.

https://infoventure.tsx.com/TSXVenture/TSXVentureHttpController?GetPage=SecuritySummary&SECURITY_ID=226501&MARKET_ID=CDNX&SEC_SYM_SID=1&HC_FLAG1=on